Astepro Launch And Strong Cold Season Boost Bayer In Q3
The US OTC launch of reclassified nasal spray Astepro Allergy, in combination with “continuously elevated cold incidence rates,” helped to drive up Bayer's Consumer Health sales at a double-digit rate in Q3.
You may also be interested in...
Major Europe-based consumer health players Reckitt, Bayer, Haleon and Sanofi all feature in this sales and earnings preview, which highlights what to look out for and potential talking points as these four companies report third-quarter results over the coming weeks.
Campaign featuring actress Meghann Fahy says "allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.” Ads launch two months after FDA granted tentative approval for two ANDAs for generic equivalents, indicating approval could come pending resolution of patent litigation.
Beating global market growth, continuing macroeconomic headwinds and spin-off perspectives were among the key talking points as Bayer Consumer Health reported its 2022 sales and earnings.